DES Breast Cancer Trial BREAKING News Update: Day two and the trial is over!

Breaking news at the conclusion of the trial today January 9, 2012

Dr. Hans-Olov Adami, the Harvard Department of Publish Health, testified that the evidence is so compelling that even the Harvard Women's Health Watch and the Institute of Medicine of the National Academies stated that mothers and daughters "who were exposed to pharmacological levels of DES in utero experienced important and devastating effects many years later, including an elevated risk of breast cancer"

Dr. Adami testified that epidemiological evidence was not only applicable to the DES daughters, but to ANY DES daughter who developed breast cancer above the age of 40 or 50 so long as they did not have any other unusually high breast cancer risk factors.

He testified that the experiment on women in the case of DES was truly a human tragedy, as he published in the European Journal of Epidemiology.

Eli Lilly did not even complete their cross examination of Dr. Adami, when they, during a break, approached the Plaintiffs and the Judge to settle the case with an undisclosed sum.

Updates will continue as they are received!